NCT00002222已完成不适用
An Open Label Study of the Safety and Tolerability of Valganciclovir, an Oral Prodrug of Ganciclovir, for the Treatment of Cytomegalovirus Retinitis in Subjects With AIDS
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 200
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to see if valganciclovir is a safe treatment for CMV retinitis in patients who have been treated for this condition in the past. This study also examines the effectiveness of valganciclovir in preventing the recurrence of CMV retinitis.
详细描述
Patients receive valganciclovir twice a day for 21 days as induction therapy then daily as maintenance therapy. Patients are encouraged to remain on study for at least 3 months and will remain until common study closure.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
3 期
Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by InjectionCytomegalovirus RetinitisHIV InfectionsNCT00017784Hoffmann-La Roche500
已完成
1 期
A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of AgeCytomegalovirus Infections, Heart TransplantationNCT01165580Hoffmann-La Roche17
终止
2 期
Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired InfantsCmv CongenitalCMVCongenital CmvSNHLSensorineural Hearing LossNCT03107871Albert Park10
已完成
不适用
An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous AccessCytomegalovirus RetinitisHIV InfectionsNCT00002135Hoffmann-La Roche
已完成
不适用
Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) InfectionCytomegalovirus InfectionGlioblastoma MultiformeNCT00400322Karolinska Institutet42